1. Cyclosporine A inhibits TGF-β2-induced myofibroblasts of primary cultured human pterygium fibroblasts.
- Author
-
Gum SI, Kim YH, Jung JC, Kim IG, Lee JS, Lee KW, and Park YJ
- Subjects
- Actins metabolism, Cell Differentiation, Cells, Cultured, Female, Fibronectins metabolism, Humans, Immunosuppressive Agents pharmacology, Inflammation, Laminin metabolism, Male, Microscopy, Fluorescence, Muscle, Smooth metabolism, Myofibroblasts metabolism, Oligonucleotides chemistry, Pterygium surgery, Signal Transduction, Software, Transforming Growth Factor beta2 pharmacology, Cyclosporine pharmacology, Fibroblasts metabolism, Pterygium drug therapy, Pterygium metabolism
- Abstract
Cyclosporine A (CsA), an immunomodulatory drug, and is increasingly used to treat moderate dry eye syndrome and ocular surface inflammation. However, any inhibitory effect on differentiation of fibroblasts to myofibroblasts remains unclear. Here, we show that the inhibitory effect of CsA on transforming growth factor-beta2 (TGF-β2)-induced myofibroblasts in primary cultured human pterygium fibroblasts. CsA significantly decreased mRNA and protein expression of myofibroblast-related markers including α-SMA, laminin, and fibronectin. These findings were supported by the results from immunofluorescence staining. Taken together, these results indicate the therapeutic potential of CsA against pterygium progression. Further studies are necessary to elucidate the precise intracellular signal mechanism responsible for CsA-induced downregulation of myofibroblast markers in pterygium fibroblasts., (Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF